Medpace (NASDAQ:MEDP) CEO August Troendle Sells 8,770 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 8,770 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $621.29, for a total transaction of $5,448,713.30. Following the completion of the transaction, the chief executive officer directly owned 515,153 shares in the company, valued at $320,059,407.37. This represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Medpace Stock Performance

Medpace stock traded down $1.15 during trading hours on Thursday, reaching $615.29. 221,328 shares of the stock were exchanged, compared to its average volume of 333,335. The stock has a market cap of $17.17 billion, a P/E ratio of 36.07, a P/E/G ratio of 2.77 and a beta of 1.15. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The firm’s 50 day moving average is $582.78 and its 200 day moving average is $508.65.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the previous year, the firm earned $3.10 earnings per share. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several recent analyst reports. TD Cowen boosted their target price on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Barclays set a $600.00 price target on Medpace in a research note on Thursday, July 23rd. Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $535.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Finally, Mizuho raised their target price on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $595.20.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in MEDP. Johnson Financial Group Inc. acquired a new stake in shares of Medpace during the 2nd quarter valued at approximately $27,000. Elyxium Wealth LLC acquired a new stake in shares of Medpace in the 4th quarter worth approximately $30,000. Jones Financial Companies Lllp purchased a new position in Medpace in the 2nd quarter valued at approximately $30,000. Allied Private Wealth LLC purchased a new position in Medpace in the 2nd quarter valued at approximately $31,000. Finally, Kilter Group LLC purchased a new position in Medpace in the 2nd quarter valued at approximately $31,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.